Phase 2, Observer-Blind, Placebo-Controlled, Randomized, Multi-Center Extension Study to Evaluate the Safety and Immunogenicity of a Booster Dose of a MenABCWY Vaccine Administered 24 Months Following the Primary Series to Adolescents and Young Adults Who Participated in V102_03 (NCT01272180)

Trial Profile

Phase 2, Observer-Blind, Placebo-Controlled, Randomized, Multi-Center Extension Study to Evaluate the Safety and Immunogenicity of a Booster Dose of a MenABCWY Vaccine Administered 24 Months Following the Primary Series to Adolescents and Young Adults Who Participated in V102_03 (NCT01272180)

Completed
Phase of Trial: Phase II

Latest Information Update: 30 Oct 2016

At a glance

  • Drugs Meningococcal vaccine groups A B C Y W-135 conjugate (Primary) ; OMV
  • Indications Meningococcal group A infections; Meningococcal group B infections; Meningococcal group C infections; Meningococcal group W-135 infections; Meningococcal group Y infections; Meningococcal infections
  • Focus Therapeutic Use
  • Sponsors GlaxoSmithKline; Novartis Vaccines
  • Most Recent Events

    • 22 May 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 05 May 2014 Planned End Date changed from 1 Sep 2015 to 1 Jun 2015 as reported by ClinicalTrials.gov record.
    • 05 May 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top